Analysis of related clinical risk factors of lung infection in patients with lung cancer
-
摘要:
目的 肺癌患者由于营养不良、放化疗等更容易发生感染,本文旨在对发生肺部感染的相关危险因素进行探究。 方法 回顾性研究2014年1月—2016年12月杭州市肿瘤医院收治的肺癌患者156例。肺部感染的定义为胸片显示存在新发的或正在进行的浸润性病变以及合并出现以下任何一项:新发化脓性痰、慢性痰液性质改变或发热。通过多变量Cox回归分析探究与肺部感染显著相关的危险因素。 结果 所有研究对象中60例(38.5%)出现肺部感染,直至随访结束,肺炎组患者的平均总生存率显著短于非肺炎组患者(48.5% vs. 74.2%,P < 0.05);既往吸烟(32.8%)与正在吸烟(19.6%)患者的总生存率低于从不吸烟者(75.4%),差异有统计学意义(P < 0.001);多因素分析显示年龄(P=0.001)、临床Ⅳ期(P=0.045)、中性粒细胞减少症(P < 0.001)、吸烟(P=0.020)是肺癌患者发生肺部感染的独立危险因素。接受化疗的患者亚组分析中显示年龄(P=0.006)、中性粒细胞减少症(P < 0.001)和吸烟(P=0.030)、二线治疗(P=0.004)是肺炎发展的独立危险因素。 结论 对于肺癌患者,老年、吸烟和中性粒细胞减少症是影响其肺部感染的显著危险因素。 Abstract:Objective To explore the relevant risk factors for lung infection. Methods We conducted a retrospective study of 156 lung cancer patients admitted to Hangzhou Cancer Hospital from January 2014 to December 2016. Pulmonary infection was defined as a chest radiograph showing the presence of new or ongoing infiltrating lesions combined with any of the following: new purulent sputum, changes chronic sputum, or fever. Multivariate cox regression analysis was used to explore the risk factors that were significantly related to lung infection. Results A total of 60 cases (38.5%) of all study subjects developed pulmonary infections. Until the end of follow-up, the average overall survival rate of patients in the pneumonia group was significantly shorter than that of patients in the non-pneumonia group (48.5% vs. 74.2%, P < 0.05). The overall survival rate of smoking patients was significantly lower than that of never-smokers (32.8% vs. 19.6% vs. 75.4%, P < 0.001). Multivariate analysis showed that age (P=0.001), clinical stage Ⅳ (P=0.045), neutropenia (P < 0.001), and smoking (P=0.020) were independent risk factors for lung infection in patients with lung cancer. A subgroup analysis of patients receiving chemotherapy showed that age (P=0.006), neutral granulocytopenia (P < 0.001), smoking (P=0.030), and second-line therapy (P=0.004) were independent risk factors for the development of pneumonia. Conclusion For lung cancer patients, old age, smoking, and neutropenia are significant risk factors affecting their lung infections. -
Key words:
- Lung cancer /
- Lung infection /
- Pneumonia /
- Risk factors /
- Multivariate analysis
-
表 1 2组患者基线特征信息统计
组别 例数 年龄(x±s,岁) 性别(男/女,例) BMI (x±s) 吸烟史[例(%)] 中性粒细胞减少 从不吸烟 既往吸烟 当下吸烟 每年包数(x±s) 肺炎组 60 69.62±4.25 45/15 23.26±2.02 9(15.0) 26(43.3) 25(41.7) 39.42±20.36 26(43.3) 非肺炎组 96 67.36±3.66 52/44 23.45±3.17 32(33.3) 36(37.5) 28(29.2) 39.75±21.04 18(18.8) 统计量 0.852a 5.958b -0.009a 6.405b 0.525b 2.572b -0.289a 11.019b P值 0.419 0.062 0.993 0.011 0.469 0.109 0.780 0.001 注:a为t值,b为χ2值。 表 2 2组肺癌患者组织病理学及临床分期比较
[例(%)] 组别 例数 组织病理类型 临床分期 腺癌 鳞癌 小细胞肺癌 腺鳞癌 大细胞癌 其他 Ⅰ Ⅱ Ⅲ Ⅳ 肺炎组 60 27(45.0) 14(23.3) 12(20.0) 1(1.7) 1(1.7) 5(8.3) 8(13.3) 5(8.3) 24(40.0) 23(38.3) 非肺炎组 96 62(64.6) 18(18.8) 8(8.3) 2(2.1) 2(2.1) 4(4.2) 32(33.3) 4(4.2) 17(17.7) 43(44.8) χ2值 5.779 0.476 4.496 0.034 0.034 1.179 7.746 1.179 9.470 0.631 P值 0.016 0.490 0.034 0.854 0.854 0.278 0.005 0.278 0.002 0.427 表 3 2组肺癌患者肺功能比较(x±s)
组别 例数 肺功能检测 FVC%预测值 FEV1%预测值 FEV1/FVC < 70% [例(%)] FEV1/FVC 肺炎组 60 82.33±15.92 78.42±19.18 29(48.3) 0.91±0.27 非肺炎组 96 85.46±14.25 83.06±20.15 38(39.6) 0.92±0.24 统计量 -0.632a -0.529a 1.154b -0.104a P值 0.545 0.446 0.283 0.857 注:a为t值,b为χ2值。FVC:用力肺活量;FEV1:第1秒用力呼气体积。 表 4 2组肺癌患者临床治疗方式比较
[例(%)] 组别 例数 无治疗 手术 化疗 酪氨酸激酶抑制剂 联合放化疗 立体定向放疗 放疗 新辅助联合放化疗 肺炎组 60 4(6.7) 13(21.7) 24(40.0) 3(5.0) 9(15.0) 0(0.0) 7(11.7) 0(0.0) 非肺炎组 96 7(7.3) 37(38.5) 26(27.1) 16(16.7) 5(5.2) 2(2.1) 2(2.1) 1(1.0) χ2值 0.030 4.828 2.829 4.699 4.334 1.266 6.238 0.629 P值 0.863 0.028 0.093 0.030 0.037 0.258 0.013 0.428 表 5 整体及亚组肺炎发生Cox多变量分析
变量 B SE Wald χ2 P值 HR 95% CI 整体肺癌患者 年龄 0.584 0.191 1.097 0.001 1.055 1.022~1.079 临床分期 Ⅰ - - - - - - Ⅱ 1.616 0.511 2.441 0.036 0.475 0.238~0.927 Ⅲ 1.808 0.619 2.837 0.685 1.231 0.508~2.945 Ⅳ 1.754 0.536 3.059 0.045 1.762 1.011~3.098 中性粒细胞减少症 0.471 0.232 3.961 < 0.001 2.625 1.547~4.305 吸烟 0.069 0.185 3.561 0.020 2.105 1.108~3.775 细胞毒性化疗亚组分析 年龄 -0.009 0.007 1.352 0.006 1.048 1.015~1.085 治疗方式 0.016 一线 - - - - - - 二线 0.966 0.736 1.315 0.004 0.402 0.208~0.782 三线以上 1.506 0.874 1.738 0.772 0.905 0.474~1.725 中性粒细胞减少症 0.766 0.293 1.563 < 0.001 3.185 1.836~5.714 吸烟 0.584 0.179 3.269 0.030 2.115 1.082~4.236 注:“-”表示以变量赋值中最小值为参照。 -
[1] 王鹏, 张东, 郭学光, 等. 老年非小细胞肺癌患者肺部感染病原学分布与耐药性分析[J]. 现代生物医学进展, 2017, 17(32): 6260-6266. https://www.cnki.com.cn/Article/CJFDTOTAL-SWCX201732012.htm [2] 郝名浩, 吴畴斌, 石荣跃, 等. 老年中心型肺癌并发阻塞性肺炎的病原学特点及耐药性分析[J]. 现代肿瘤医学, 2018, 26(14): 2203-2205. doi: 10.3969/j.issn.1672-4992.2018.14.015 [3] 彭武君, 张文林, 刘君德, 等. 气道定植菌对肺癌患者术后肺部感染的影响因素分析[J]. 中华医院感染学杂志, 2019, 29(4): 508-511. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHYY201904007.htm [4] XU M Y, CAO B, CHEN Y, et al. Association between Helicobacter pylori infection and tumor markers: an observational retrospective study[J]. BMJ Open, 2018, 8(8): e022374. doi: 10.1136/bmjopen-2018-022374 [5] 吴海玲, 刘宁红. 老年肺癌患者医院获得性肺炎临床分析[J]. 中华老年多器官疾病杂志, 2017, 16(1): 43-46. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLQG201701013.htm [6] YAMAGUCHI F, MINAKATA T, MIURA S, et al. Heterogeneity of latent tuberculosis infection in a patient with lung cancer[J]. J Infect Public Health, 2020, 13(1): 151-153. doi: 10.1016/j.jiph.2019.07.009 [7] LEE P H, LEE T Y, CHANG G C. Hepatitis B flare during osimertinib targeted therapy in a lung cancer patient with a resolved hepatitis B virus infection[J]. Eur J Cancer, 2020, 130: 272-274. doi: 10.1016/j.ejca.2020.02.026 [8] 李啸, 徐静. 肺癌与肺炎合并伴胸腔积液患者的急诊疗效及血浆B型钠尿肽、降钙素原水平的变化比较[J]. 中国医药导报, 2018, 15(26): 121-124. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY201826031.htm [9] XIONG W M, XU Q P, LI X, et al. The association between human papillomavirus infection and lung cancer: a system review and meta-analysis[J]. Oncotarget, 2017, 8(56): 96419-96432. doi: 10.18632/oncotarget.21682 [10] NAGY A, MULLER V, KOLONICS-FARKAS A M, et al. Worse lung cancer outcome in patients with lower respiratory tract infection confirmed at time of diagnosis[J]. Thorac Cancer, 2019, 10(9): 1819-1826. doi: 10.1111/1759-7714.13153 [11] 孙燕, 胡予. 合并症对老年肺癌患者化疗耐受性及生存期的影响[J]. 中国临床医学, 2018, 25(3): 333-339. https://www.cnki.com.cn/Article/CJFDTOTAL-LCYX201803004.htm [12] KRELING G A D, DAGOSTIN M A, PARK M. Empyema caused by infection with Clostridium septicum in a patient with lung cancer[J]. J Bras Pneumol, 2018, 44(6): 529-531. doi: 10.1590/s1806-37562017000000466 [13] MERCIER T, DESLYPERE G, NACKAERTS K. Ramsay Hunt syndrome: a rare complication of herpes zoster infection in a lung cancer patient[J]. Acta Clin Belg, 2019, 74(5): 355-358. doi: 10.1080/17843286.2018.1517076 [14] 高珂, 赖玉田, 黄健, 等. 肺癌肺叶切除患者术前存在气道定植菌与术后肺炎的发生有相关性吗?[J]. 中国肺癌杂志, 2017, 20(4): 239-247. https://www.cnki.com.cn/Article/CJFDTOTAL-FAIZ201704005.htm [15] GARG N, PUNCH C, STEIN M, et al. When occam's razor can fail- active mycobacteria infection and lung cancer: a case of neuroendocrine lung cancer diagnosed in the setting of refractory mycobacterium avium-intracellulare[J]. Clin Case Rep, 2018, 6(11): 2156-2159. doi: 10.1002/ccr3.1813 [16] CHEN S, LI X, LV H, et al. Prognostic dynamic nomogram integrated with inflammation-based factors for non-small cell lung cancer patients with chronic hepatitis B viral infection[J]. Int J Biol Sci, 2018, 14(13): 1813-1821. doi: 10.7150/ijbs.27260 [17] 叶红英, 应俊, 方和敬, 等. 慢性肾衰竭维持性血液透析患者肺部感染的危险因素分析[J]. 中华全科医学, 2018, 16(6): 932-934. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201806023.htm [18] YAMASAKI M, FUNAISHI K, SAITO N, et al. Small-cell lung cancer comorbid with pulmonary mycobacterium avium infection: a case report[J]. Chemotherapy, 2018, 63(5): 257-261. doi: 10.1159/000494504 [19] 彭伟, 陈津, 魏伟, 等. 血清KL-6预测肺癌患者放疗后发生放射性肺炎风险的研究[J]. 中华放射医学与防护杂志, 2017, 37(12): 891-895. doi: 10.3760/cma.j.issn.0254-5098.2017.12.002 [20] TAMURA A, FUKAMI T, HEBISAWA A, et al. Recent trends in the incidence of latent tuberculosis infection in Japanese patients with lung cancer: A small retrospective study[J]. J Infect Chemother, 2020, 26(3): 315-317. doi: 10.1016/j.jiac.2019.10.018 [21] WANG Y H, SHEN X D. Human immunodeficiency virus infection and mortality risk among lung cancer patients: a systematic review and meta-analysis[J]. Medicine(Baltimore), 2018, 97(15): e0361. http://europepmc.org/abstract/MED/29642182